Non-valvular atrial fibrillation
Conditions
Interventions
None listed
Sponsors
Pfizer Japan Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Male or female subjects with age >= 20 years 2.Patients with non-valvular atrial fibrillation necessary to be treated with an anticoagulant for prevention of ischemic stroke and systemic embolism; 3.Patients treated with warfarin at least for 8 weeks, who agree to switch from warfarin to apixaban 4.Patients who have never been treated with any NOAC including apixaban 5.Patients who provide written informed consent.
Exclusion criteria
Exclusion criteria: 1.Patients whose warfarin is switched to apixaban at the timing of invasive procedures other than catheter ablation for treatment of AF. 2.Patients with a history of hypersensitivity to the active substance (apixaban) or to any of the excipients of this drug 3.Patients with clinically significant active bleeding. (judged by a physician in charge of the patients) 4.Patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk. (judged by a physician in charge of the patients) 5.Patients with renal failure (creatinine clearance <15 mL/min) (No clinical experience) 6.Patients who are not able to answer to the questionnaires.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Changes in patient satisfaction from at 12 weeks after switching to apixaban from baseline, assessed by using ACTS (Burdens). 2.Changes in patient satisfaction at 12 weeks after switching to apixaban from baseline, assessed by using ACTS (Benefits). | — |
Countries
Japan
Contacts
Public ContactTomomi Imai
Mebix Inc. Clinical Research Division
Outcome results
None listed